Expression of metallothionein mRNAs on mouse cerebellum microglia cells by thimerosal and its metabolites.
Effects of thimerosal and its metabolites, ethyl mercury and thiosalicylate, on the expression of metallothionein (MT) mRNAs in mouse cerebellum microglia cell line, C8-B4 cells, were studied. The level of MT-1 mRNA significantly decreased at early hours and recovered time-dependently 24h after thimerosal was added to the C8-B4 cells. However, MT-2 and MT-3 mRNA expressions did not change from the control group. In contrast, the expression of MT-1 mRNA increased in a mouse neuroblastoma cell line 6h after incubation with thimerosal. In addition, the level of MT-1 mRNA decreased in C8-B4 cells 6h after the addition of thiosalicylate, but ethyl mercury induced MT-1 mRNA expression. When cell viability was compared with thimerosal, thiosalicylate, and ethyl mercury, the viability of C8-B4 cells decreased dose-dependently 24h after either thimerosal or ethyl mercury was added; however, the viability increased dose-dependently until 15 microM thiosalicylate was added. From the present results, it is concluded that the expression of MT-1 mRNA may be mediated by different factors than the expression of MT-2 mRNA in C8-B4 cells. The reduction of MT-1 mRNA level by thiosalicylate may affect the proliferation of C8-B4 cells.
Minami
Takeshi
T
Department of Life Sciences, School of Science & Engineering, Kinki University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan. minamita@life.kindai.ac.jp
Miyata
Eriko
E
Sakamoto
Yamato
Y
Kohama
Azusa
A
Yamazaki
Hideo
H
Ichida
Seiji
S
D000818:Animals; D001711:Biotransformation; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002531:Cerebellum / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein; D008668:Metallothionein / Q000235:genetics*; D000090023:Metallothionein 3; D051379:Mice; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000235:genetics; D011310:Preservatives, Pharmaceutical / Q000378:metabolism / Q000633:toxicity*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D012459:Salicylates / Q000378:metabolism / Q000633:toxicity*; D013438:Sulfhydryl Compounds / Q000378:metabolism / Q000633:toxicity*; D013849:Thimerosal / Q000378:metabolism / Q000633:toxicity*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D000509:alpha-Fetoproteins / Q000235:genetics
D005904:Glial Fibrillary Acidic Protein; D000090023:Metallothionein 3; C491054:Mt2 protein, mouse; C000715430:Mt3 protein, mouse; D009419:Nerve Tissue Proteins; D011310:Preservatives, Pharmaceutical; D012333:RNA, Messenger; D012459:Salicylates; D013438:Sulfhydryl Compounds; D042461:Vascular Endothelial Growth Factor A; D000509:alpha-Fetoproteins; C528900:glial fibrillary astrocytic protein, mouse; C525355:metallothionein-1, mouse; C467480:vascular endothelial growth factor A, mouse; D013849:Thimerosal; D008668:Metallothionein; C441201:thiosalicylic acid